Home › Compare › NMTAF vs MRK

NMTAF vs MRK: Dividend Comparison 2026

NMTAF yields 9090.91% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTAF wins by $11484.33M in total portfolio value
10 years
NMTAF
NMTAF
● Live price
9090.91%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11484.38M
Annual income
$495,914,398.83
Full NMTAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NMTAF vs MRK

📍 NMTAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTAF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NMTAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTAF
Annual income on $10K today (after 15% tax)
$772,727.27/yr
After 10yr DRIP, annual income (after tax)
$421,527,239.01/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NMTAF beats the other by $421,518,910.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTAF + MRK for your $10,000?

NMTAF: 50%MRK: 50%
100% MRK50/50100% NMTAF
Portfolio after 10yr
$5742.22M
Annual income
$247,962,098.48/yr
Blended yield
4.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NMTAF
No analyst data
Altman Z
-8.7
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTAF buys
0
MRK buys
0
No recent congressional trades found for NMTAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTAFMRK
Forward yield9090.91% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7% ✓
Portfolio after 10y$11484.38M ✓$56.8K
Annual income after 10y$495,914,398.83 ✓$9,798.13
Total dividends collected$9168.85M ✓$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NMTAF vs MRK ($10,000, DRIP)

YearNMTAF PortfolioNMTAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$465,245$454,545.45$11,206$366.19+$454.0K → NMTAF
2$10,379,832$9,882,019.00$12,650$502.35+$10.37M → NMTAF
3$114,130,817$103,024,397.10$14,407$694.19+$114.12M → NMTAF
4$651,465,108$529,345,133.88$16,585$967.82+$651.45M → NMTAF
5$2,108,998,381$1,411,930,715.13$19,342$1,363.89+$2108.98M → NMTAF
6$4,392,546,872$2,135,918,605.11$22,913$1,947.19+$4392.52M → NMTAF
7$6,778,817,377$2,078,792,223.88$27,662$2,823.89+$6778.79M → NMTAF
8$8,752,449,215$1,499,114,620.77$34,159$4,173.35+$8752.42M → NMTAF
9$10,269,596,002$904,475,342.71$43,337$6,308.80+$10269.55M → NMTAF
10$11,484,382,121$495,914,398.83$56,776$9,798.13+$11484.33M → NMTAF

NMTAF vs MRK: Complete Analysis 2026

NMTAF — Stock

Neometals Ltd engages in the development and commercialisation of sustainable processing solutions that recycle and recover critical materials from waste streams in Australia. The company operates through three segments: Lithium, Titanium/Vanadium, and Other. Its projects include the Barrambie Gold project covering an area of 505 square kilometers located in Sandstone, Western Australia; Lithium Chemicals project; Vanadium Recovery project, which produces vanadium pentoxide from steelmaking by-products. Neometals Ltd was incorporated in 2001 and is based in West Perth, Australia.

Full NMTAF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NMTAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTAF vs SCHDNMTAF vs JEPINMTAF vs ONMTAF vs KONMTAF vs MAINNMTAF vs JNJNMTAF vs ABBVNMTAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.